Back to Awarded Treatment Trials


Awarded Trial: 05T-705

Grant ID

05T-705

Illness

Schizophrenia

Primary Drug/Intervention

Rasagiline

Primary Dosage

2 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Buchanan

Sample Size

60

Duration of Study Period for Each Subject

16 weeks

Outcome Measurements

Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Calgary Depression Scale, Clinical Global Impression Scale, Schedule for the Deficit Syndrome, Simpson-Angus Extrapyramidal Symptom Rating Scale, Barnes Akathisia Scale

Results

Rasagiline 3 mg./day, an MAO-B inhibitor, was used as an adjuct for 60 patients with schizophrenia or schizoaffective disorder randomized to drug or placebo for 12 weeks. There was a trend toward greater improvement on the SANS for rasagiline (p=0.11) but it did not achieve significance. Rasagiline had no effect on cognitive symptoms.

Publication

Being submitted.

Link

N/A

PI Name

Robert Buchanan

Degree

MD

Center

Maryland Psychiatric Research Center

Institution

University of Maryland School of Medicine

Address

P.O. Box 21247

City or Town

Baltimore

State or Province

MD

Zip or Postal Code

21228

Country

USA

Email Address

rwbuchanan@mprc.umaryland.edu